Huihe Medical Launches Multicenter Clinical Trial of Second-Generation C-Wave® II Coronary Intravascular Lithotripsy System with Academician Ge Junbo at CTCC 2024
H&H Healthcare
R&D and Producer of Interventional Medical Devices for Heart Disease
The 6th "Rudao Heart Science" International Cardiovascular Disease Conference (CTCC 2024) Scheduled for8Month15-18Recently held in Hefei, Anhui, the ancient land of the Three Kingdoms, a city renowned for science and education, and a hub of innovation.
With the widespread adoption of coronary artery shock wave technology (IVL) globally,HuiHe Healthcare has launched its innovative R&D advantages and globally patented helical shockwave technology.2On behalf ofIVL: C-Wave® IICoronary Shock Wave System.
To provide further evidence-based support for the application of shock wave technology in the treatment of coronary artery calcification, Zhongshan Hospital Affiliated to Fudan UniversityAcademician Ge JunboJoin Hands with HuiHe Healthcare，Co-initiatedC-Wave® IIMulticenter Clinical Trial in China.HuiHe HealthcareWill be8Month16Day, in the sub-venue7Hold“HuiHe HealthcareIIChina Multicenter Study Investigators' Meeting on Coronary Shockwave Balloon”，We sincerely invite you to attend!
